Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.
M C F J de RotteP H P de JongS M F PluijmM Bulatović CalasanP J BarendregtD van ZebenP A van der LubbeP B de SonnavilleJ LindemansJ M W HazesR de JongePublished in: Arthritis and rheumatism (2014)
A low baseline concentration of erythrocyte folate is associated with high disease activity and nonresponse at 3 months after the start of MTX treatment and could be used in prediction models for MTX outcome. None of the investigated one-carbon metabolism biomarkers were associated with incidence of adverse events at 3 months.